Reckitt CEO's $17B Predicament Post author:Sam Post published:December 26, 2017 Post category:BioPharma 2018 is the year for Rakesh Kapoor to show he’s worth it. Source: BioSpace You Might Also Like Addex Therapeutics Shareholders Approved All Board Proposals At 2017 Annual General Meeting June 22, 2017 Teva Sees Approval at Finish Line for Anti-CGRP Migraine Treatment December 21, 2017 Zomedica Announces First Quarter 2017 Financial Results May 11, 2017
Addex Therapeutics Shareholders Approved All Board Proposals At 2017 Annual General Meeting June 22, 2017
